R. Heinig

发表

Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl-leukotrienes, in normal volunteers.

G. Wensing, R. Heinig, J. Kuhlmann, 1996, British journal of clinical pharmacology.

Pupil reaction: a valid sensitive clinical biomarker for 5-HT compounds.

J. Kuhlmann, G. Wensing, M. Boettcher, 2005, Basic & clinical pharmacology & toxicology.

Effect of BAY x7195, an oral receptor antagonist of cysteinyl-leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers

G. Wensing, R. Heinig, J. Kuhlmann, 2007, European Journal of Clinical Pharmacology.

Prediction of a potentially effective dose in humans for BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein (CETP) by allometric species scaling and combined pharmacodynamic and physiologically-based pharmacokinetic modelling.

Stefan Willmann, Carsten Schmeck, F. Hafner, 2012, British journal of clinical pharmacology.

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

Martin Büchert, Ulrike Fasol, Oliver Boix, 2012, Clinical Cancer Research.

Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes.

R. Heinig, H. Stass, G. Blaschke, 1998, Journal of chromatography. B, Biomedical sciences and applications.

The Pharmacological Basis for Metrifonate’s Favourable Tolerability in the Treatment of Alzheimer’s Disease

R. Heinig, B. Schmidt, 1998, Dementia and Geriatric Cognitive Disorders.

BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury.

C. Weinz, S. Sandmann, T. Schwarz, 2006, CNS drug reviews.

Proposal for defining the relevance of drug accumulation derived from single dose study data for modified release dosage forms

R. Heinig, W. Mueck, Christian Scheerans, 2015, Biopharmaceutics & drug disposition.

Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis

T. Eissing, R. Heinig, J. Lippert, 2021, Clinical Pharmacokinetics.

Population Pharmacokinetic and Exposure–Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease

B. Ploeger, T. Eissing, J. Lippert, 2019, Clinical Pharmacokinetics.

Evaluation of interethnic differences in repinotan pharmacokinetics by using population approach.

S. Higuchi, R. Heinig, Takahiko Tanigawa, 2006, Drug metabolism and pharmacokinetics.

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

R. Heinig, A. Halabi, J. Nagelschmitz, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

Clinical Pharmacokinetics of Nisoldipine Coat-Core

R. Heinig, 1998, Clinical pharmacokinetics.

Single dose pharmacokinetics, pharmacodynamics, tolerability and safety of BAY 60-5521, a potent inhibitor of cholesteryl ester transfer protein.

C. Kohlsdorfer, G. Wensing, M. Boettcher, 2012, British journal of clinical pharmacology.

Disposition of a Single Dose of Warfarin in Healthy Individuals after Pretreatment with Metrifonate

N. Kitchin, R. Heinig, P. Rolan, 1999 .

Results From Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3

R. Heinig, J. Nagelschmitz, Sebastian Wertz, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone

T. Eissing, R. Heinig, S. Frechen, 2021, CPT: pharmacometrics & systems pharmacology.

Pharmacokinetics of Escalating Doses of Intravenous Repinotan in Healthy Male Volunteers

R. Heinig, M. Böttcher, 2005, Clinical drug investigation.

Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro

M. Radtke, T. Schwarz, R. Heinig, 2018, Drug Metabolism and Disposition.

Abstract 1666: Regorafenib (BAY 73-4506): preclinical pharmacology and clinical identification and quantification of its major metabolites

D. Zopf, K. Thierauch, S. Wilhelm, 2010 .

Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma (CRC).

M. Büchert, D. Strumberg, M. Scheulen, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug–Drug Interaction Studies In Vitro and In Vivo

R. Heinig, J. Nagelschmitz, M. Gerisch, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Reduced Plasma Nisoldipine Concentrations in Phenytoin‐Treated Patients with Epilepsy

R. Michelucci, C. Tassinari, E. Perucca, 1996, Epilepsia.

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study

M Büchert, M Jeffers, M. Büchert, 2012, British Journal of Cancer.

Pharmacokinetics of a New Orodispersible Tablet Formulation of Vardenafil

R. Heinig, H. Dietrich, Boris Weimann, 2011, Clinical drug investigation.

Results from Drug–Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications

Michaela Bairlein, R. Heinig, J. Nagelschmitz, 2020, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment

R. Heinig, A. Halabi, S. Lentini, 2016, Clinical pharmacology in drug development.

Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone – results from first‐in‐man and relative bioavailability studies

G. Wensing, R. Heinig, S. Lentini, 2016, Fundamental & clinical pharmacology.

Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers

R. Heinig, J. Nagelschmitz, Stephanie Loewen, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Determination of finerenone - a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma.

R. Heinig, Stephanie Loewen, G. Rohde, 2021, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Pharmacokinetics of Metrifonate and its Metabolite Dichlorvos in Healthy Volunteers and in Patients with Renal Impairment

R. Heinig, A. Halabi, H. Dietrich, 1999 .

Effects of a Magnesium/Aluminium Hydroxide-Containing Antacid,Cimetidine or Ranitidine on the Pharmacokinetics of Metrifonate and its Metabolite DDVP

M. Boettcher, R. Heinig, Z. Herman-Gnjidic, 1999 .

Development, validation and application of assays to quantify metrifonate and 2,2-dichlorovinyl dimethylphosphate in human body fluids.

R. Heinig, D. Zimmer, G. Krol, 2000, Journal of chromatography. B, Biomedical sciences and applications.

39-26 Rapid attainment of steady-state acetylcholinesterase inhibition by administration of metrifonate loading and maintenance doses once-daily in elderly volunteers

M. Versavel, J. Kuhlmann, R. Heinig, 1997, Biological Psychiatry.

The effect of food and time of administration on the pharmacokinetic and pharmacodynamic profile of metrifonate.

R. Heinig, R. Sachse, 1999, International journal of clinical pharmacology and therapeutics.

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment

R. Heinig, A. Halabi, J. Nagelschmitz, 2019, European Journal of Drug Metabolism and Pharmacokinetics.

R. Heinig, J. Nagelschmitz, M. Gerisch, 2018, European Journal of Drug Metabolism and Pharmacokinetics.

Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form

R. Heinig, J. Kuhlmann, G. Ahr, 1997, European Journal of Clinical Pharmacology.

Phase I study of BAY 73–4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors: Final results of a dose-escalation study

C. Unger, D. Strumberg, M. Scheulen, 2008 .

The effect of ketoconazole on the pharmacokinetics, pharmacodynamics and safety of nisoldipine

R. Heinig, G. Ahr, H. Adelmann, 1999, European Journal of Clinical Pharmacology.

Determination of the enantiomers of nisoldipine in human plasma using high-performance liquid chromatography on a chiral stationary phase and gas chromatography with mass-selective detection.

R. Heinig, G. Ahr, V. Muschalek, 1994, Journal of chromatography. B, Biomedical applications.

Pharmacokinetics and pharmacodynamics of the acetylcholinesterase inhibitor metrifonate in patients with renal impairment.

R. Heinig, A. Halabi, J. Dingemanse, 1999, Therapeutic drug monitoring.

Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94–8862) in Individuals With Renal Impairment

R. Heinig, A. Halabi, S. Lentini, 2016, Clinical pharmacology in drug development.